编辑丨王多鱼排版丨水成文抗 PD-1 联合仑伐替尼（lenvatinib，一种多靶点受体酪氨酸激酶抑制剂）治疗在多种肿瘤中均显示出临床疗效，但潜在的免疫学机制尚不清楚。2025 年 1 月 30 ...

浙江大学医学院蔡志坚教授联合浙江农林大学冯华军教授等，在 Cell 子刊 Cell Reports Medicine 上发表了题为： MFGE8 induces anti-PD-1 therapy resistance by promoting ...

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...

The following is a summary of “Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...

Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...

Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...